Intravitreal Ranibizumab versus Thermal Laser Photocoagulation in the Treatment of Extrafoveal Classic Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

被引:9
|
作者
Ladas, Ioannis D. [1 ]
Chatziralli, Irini P. [1 ]
Kotsolis, Athanasios I. [1 ]
Douvali, Maria [2 ]
Georgalas, Ilias [1 ]
Theodossiadis, Panagiotis G. [2 ]
Rouvas, Alexandros A. [2 ]
机构
[1] Univ Athens, Med Sch Athens, Dept Ophthalmol 1, Athens, Greece
[2] Univ Athens, Med Sch Athens, Dept Ophthalmol 2, Athens, Greece
关键词
Age-related macular degeneration; Extrafoveal choroidal neovascularization; Ranibizumab; Thermal laser; VERTEPORFIN PHOTODYNAMIC THERAPY; SUBGROUP ANALYSIS; JUXTAFOVEAL; MARINA;
D O I
10.1159/000337347
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background: To compare the efficacy of thermal laser photocoagulation versus intravitreal ranibizumab for the treatment of extrafoveal classic choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Methods: We conducted a retrospective study on 24 eyes with extrafoveal classic CNV secondary to AMD, treated either with thermal laser photocoagulation (group 1) or with intravitreal ranibizumab (group 2). Visual acuity, number of injections/sessions and recurrence rate were assessed. Results: The mean follow-up time was 23.6 +/- 2.26 and 19.1 +/- 9.74 months for group 1 and 2, respectively. Mean best corrected visual acuity (BCVA) of groups 1 and 2 was 0.59 +/- 0.32 and 0.46 +/- 0.30 logMAR, respectively (p = 0.343). At the end of the follow-up, mean BCVA of group 1 was 0.92 +/- 0.35 and of group 20.16 +/- 0.12 logMAR and differed statistically compared to baseline (p = 0.02 and p = 0.006, respectively). There was a statistically significant difference between the two groups as far as BCVA at the end of the follow-up was concerned (p < 0.0001). The patients in group 1 received on average 1.38 sessions of thermal laser photocoagulation, while patients in group 2 received on average 4 injections of ranibizumab. The recurrence rate in the laser group was 84.6%, while in the ranibizumab group it was 18.2% (p < 0.001). Specifically, the mean time of recurrence in the laser group was 11.5 months, whereas in the ranibizumab group it was 18 months (p = 0.048). Conclusion: Intravitreal ranibizumab showed promising results in BCVA improvement and decrease in macular thickness in patients with extrafoveal classic CNV due to AMD, with a small number of injections. Laser photocoagulation treatment presented worsening in BCVA and high recurrence rate in our study with long-term follow-up. Copyright (C) 2012 S. Karger AG, Basel
引用
收藏
页码:93 / 101
页数:9
相关论文
共 50 条
  • [1] INTRAVITREAL RANIBIZUMAB FOR NAIVE EXTRAFOVEAL CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION
    Parodi, Maurizio B.
    Iacono, Pierluigi
    La Spina, Carlo
    Iuliano, Lorenzo
    Lo Giudice, Giuseppe
    Introini, Ugo
    Bandello, Francesco
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2014, 34 (11): : 2167 - 2170
  • [2] Ranibizumab for treatment of choroidal neovascularization secondary to age-related macular degeneration
    Bhatnagar, Pawan
    Spaide, Richard F.
    Takahashi, Beatriz S.
    Peragallo, Jason H.
    Freund, K. Bailey
    Klancnik, James M., Jr.
    Cooney, Michael J.
    Slakter, Jason S.
    Sorenson, John A.
    Yannuzzi, Lawrence A.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2007, 27 (07): : 846 - 850
  • [3] Extrafoveal choroidal neovascularization secondary to wet age-related macular degeneration treated with intravitreal bevacizumab
    Mones, Jordi M.
    Lopez, Mauricio A.
    Prieto, Jorge A.
    Rodriguez, Juan P.
    OPHTHALMIC SURGERY LASERS & IMAGING, 2007, 38 (03) : 226 - 228
  • [4] Intravitreal ranibizumab and bevacizumab for the treatment of nonsubfoveal choroidal neovascularization in age-related macular degeneration
    Roller, Aaron Brock
    Amaro, Miguel Hage
    ARQUIVOS BRASILEIROS DE OFTALMOLOGIA, 2009, 72 (05) : 677 - 681
  • [5] Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration
    Spaide, Richard F.
    Laud, Ketan
    Fine, Howard F.
    Klancnik, James M., Jr.
    Meyerle, Catherine B.
    Yannuzzi, Lawrence A.
    Sorenson, John
    Slakter, Jason
    Fisher, Yale L.
    Cooney, Michael J.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (04): : 383 - 390
  • [7] Intravitreal Ranibizumab for Predominantly Hemorrhagic Choroidal Neovascularization in Age-Related Macular Degeneration
    Lazzeri, Stefano
    Figus, Michele
    Sartini, Maria Sole
    Scarinci, Fabio
    Casini, Giamberto
    Guidi, Gianluca
    Cupo, Gaetano
    Cacciamani, Andrea
    Fasanella, Vincenzo
    Agnifili, Luca
    Piaggi, Paolo
    Varano, Monica
    Ripandelli, Guido
    Nardi, Marco
    Parravano, Mariacristina
    OPHTHALMOLOGICA, 2015, 233 (02) : 74 - 81
  • [8] Non-Responders to Intravitreal Ranibizumab in Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
    Iacono, Pierluigi
    Parodi, Maurizio Battaglia
    Bandello, Francesco
    OPHTHALMIC RESEARCH, 2017, 57 (01) : 42 - 47
  • [9] Photodynamic therapy and intravitreal triamcinolone for extrafoveal choroidal neovascularization in neovascular age-related macular degeneration
    Etter, Jonathan
    Fekrat, Sharon
    ANNALS OF OPHTHALMOLOGY, 2006, 38 (03) : 239 - 241
  • [10] INTRAVITREAL RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION WITH LARGE SUBMACULAR HEMORRHAGE IN AGE-RELATED MACULAR DEGENERATION
    Iacono, Pierluigi
    Parodi, Maurizio B.
    Introini, Ugo
    La Spina, Carlo
    Varano, Monica
    Bandello, Francesco
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2014, 34 (02): : 281 - 287